LONDON & NEW YORK--(BUSINESS WIRE)--This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global macro strategy provider announced they completed a definitive merger agreement. Under the terms of the agreement, Exante Data Inc will merge with and into Vanda through the acquisition by Vanda of all of the outstanding capital stock of Exante. Following the closing, Jens Nordvig will assume the role o. ...

U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Thursday.Shares of Immuneering Corp (NASDAQ:IMRX) fell sharply in pre-market trading.The company announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, with over 13 months median follow up time.Immuneering shares dipped 20.7% to $6.61 in pre-market trading.Here are some ot ...

Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and strategic buyouts.-- ARS Pharma's neffy, an emergency treatment for allergic reactions, received regulatory approval in China, while Vanda's NEREUS secured in the United States. -- FONAR Corp., the inventor of MR Scanning, is set to be taken private by its CEO-LED group. -- New analyses from InflaRx's halted phase 3 Vilobelimab trial h ...

Market Sentiment - The CNN Money Fear and Greed index showed a decline in overall market sentiment, remaining in the "Neutral" zone with a current reading of 45.8, down from 48.4 [1][4] - U.S. stocks settled lower, with the Dow Jones index falling more than 300 points, closing at 48,063.29, while the S&P 500 and Nasdaq Composite also recorded declines [1][3] Stock Performance - The S&P 500 increased by 16.39% for the year, marking its third consecutive double-digit annual surge, while the Nasdaq Composite gained 20.36% and the Dow added 12.97% in 2025 [2] - Vanda Pharmaceuticals Inc. saw its shares jump over 25% after receiving FDA approval for NEREUS, aimed at preventing motion-induced vomiting [2] - FuelCell Energy Inc. experienced an 8% decline in its shares following the filing for an amended common stock offering [2] Economic Data - U.S. initial jobless claims decreased by 16,000 to 199,000 for the week ending December 27, which was better than market estimates of 220,000 [3] - All sectors on the S&P 500 closed negatively, with real estate, industrials, and materials stocks experiencing the largest losses [3]

Core Viewpoint - B. Riley has raised the price target for Vanda Pharmaceuticals (VNDA) to $14 from $11, maintaining a Buy rating, following the FDA's approval of Nereus for motion sickness-induced vomiting prevention, indicating a positive outlook for the company as it is seen as an "ongoing turnaround story" [1] Summary by Category Company Performance - The FDA approval of Nereus is expected to unlock over $100 million in peak revenue for Vanda Pharmaceuticals [1] - The approval is also significant for the potential approval of tradipitant, which is related to GLP-1 induced nausea [1] Market Position - Vanda Pharmaceuticals is currently trading at an "excessive discount" as it approaches two more potential approvals within the next 12 months [1]

分组1 - Vanda Pharmaceuticals Inc. (VNDA) experienced a significant increase in stock price following the FDA's approval of Nereus for treating motion sickness [1] - The company is focused on developing innovative therapies, leveraging unique mechanisms of action and first-in-class treatments [1] - The analyst emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, and clinical trial design while balancing financial fundamentals [1] 分组2 - The biotech sector is characterized by the potential for breakthrough science to yield substantial returns, necessitating careful scrutiny of investment opportunities [1] - The analyst aims to provide insights that help investors understand both the opportunities and risks inherent in the biotech industry [1]

Core Viewpoint - Vanda Pharmaceuticals (VNDA.US) stock price increased by over 25.46% following the FDA approval of its new drug Nereus, which is intended for the prevention of vomiting induced by motion [1][2]. Group 1: FDA Approval and Drug Details - The FDA approval of Nereus is based on results from three clinical studies that compared the drug group with a placebo group to assess the occurrence of vomiting [2]. - Data from the trials indicated that Nereus achieved a "significant reduction" in vomiting events and demonstrated "good safety characteristics" in short-term, acute use scenarios [2]. Group 2: Market Implications - The approval of Nereus is expected to provide a new commercialization growth point for the company and further enrich its product portfolio in the central nervous system and related indications [2].

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Wednesday.The Dow traded down 0.28% to 48,229.87 while the NASDAQ slipped 0.26% to 23,359.33. The S&P 500 also fell, dropping, 0.26% to 6,878.07.Check This Out: How To Earn $500 A Month From UniFirst Stock Ahead Of Q1 EarningsLeading and Lagging SectorsUtilities shares slipped by just 0.2% on Wednesday.In trading on Wednesday, real estate stocks dipped by 0.8%.Top HeadlineU.S. crude oil inventories, exc ...

The FDA approved Vanda's drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs. ...

周三，万达生物制药(VNDA.US)股价走高，截至发稿，该股涨超32%，报9.33美元。消息面上，公司表 示，其新药Nereus已获得美国食品药品监督管理局(FDA)批准，该药物可用于预防由运动引发的呕吐。 公司称，FDA的批准决定基于三项临床研究结果。相关试验将用药组与安慰剂组进行对比，评估呕吐发 生情况。数据显示，Nereus在降低呕吐事件方面取得"显著减少"的效果，同时在短期、急性使用场景下 展现出"良好的安全性特征"。 Vanda表示，计划在未来几个月内正式推出Nereus。市场普遍认为，该药物的获批有望为公司带来新的 商业化增长点，并进一步丰富其在中枢神经及相关适应症领域的产品组合。 ...